Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | The impact of ACA in CML & the importance of monitoring these patients

Susanne Saussele • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Susanne Saussele, MD, University of Heidelberg, Mannheim, Germany, highlights the importance of monitoring in patients with chronic myeloid leukemia (CML) with additional chromosomal abnormalities (ACA). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BMS, Incyte, Novartis, Honoraria: BMS, Incyte, Novartis, Pfizer, Roche

More from Susanne Saussele

1:10
The importance of better selecting patients with CML who are eligible for treatment discontinuation
Susanne Saussele • 22 Oct 2022
1:22
Examples of challenging scenarios for TFR in CML & how to manage them
Susanne Saussele • 22 Oct 2022
4:40
Antibody responses to COVID-19 vaccines in patients with hematological malignancies
Susanne Saussele • 11 Dec 2021
3:17
Vaccination efficacy in patients with hematological malignancies
Susanne Saussele • 11 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals